GT20029

GT20029 is a small-molecule proteolysis-targeting chimera (PROTAC) designed for topical application to skin and scalp, representing the first PROTAC compound to enter and complete clinical trials via the topical route of administration. Developed by Suzhou Kintor Pharmaceutical Ltd. on a proprietary PROTAC platform employing a novel cereblon (CRBN) E3 ubiquitin ligase recruiting element (the TD-106 scaffold), GT20029 functions as a bifunctional molecular bridge: one pharmacophore engages the androgen receptor (AR) ligand-binding domain, a chemical linker spans the two recruiting elements, and a second pharmacophore recruits the CRBN-containing Cullin-RING E3 ubiquitin ligase complex, resulting in polyubiquitination and proteasomal degradation of the AR protein [1, 2]. The catalytic mechanism permits each GT20029 molecule to cycle through multiple rounds of AR degradation, enabling pharmacologically effective AR elimination at low topical concentrations. In preclinical dihydrotestosterone (DHT)-induced mouse models, GT20029 significantly promoted hair regrowth and reversed follicular miniaturization; in testosterone propionate-induced hamster flank organ models, it significantly inhibited sebaceous gland enlargement, supporting the dual indication development for androgenetic alopecia (AGA) and acne vulgaris [3].

Phase I clinical trials were completed in both China (92 subjects) and the United States (123 subjects) as randomized, double-blind, placebo-controlled studies with single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. GT20029 demonstrated excellent safety and tolerability across all dose levels, with no systemic exposure above the lower limit of quantitation (0.003 ng/mL) in the SAD cohort and maximal plasma concentrations not exceeding 0.015 ng/mL after 14 days of continuous topical application in the MAD cohort, confirming that the compound acts locally with negligible systemic absorption [3]. The Phase II trial for AGA enrolled 180 male patients with Hamilton-Norwood grade IIIv to V pattern hair loss across 12 centers in China in a multicenter, randomized, double-blind, placebo-controlled design. Patients received GT20029 solution at 0.5% or 1.0% concentration, applied in the published literature (QD) or twice weekly (BIW), for 12 weeks. The primary endpoint was the change from baseline in non-vellus target area hair count (TAHC). The 0.5% QD group demonstrated an increase of 16.80 hairs per square centimeter, 6.69 hairs per square centimeter greater than placebo (P less than 0.05); the 1.0% BIW group demonstrated an increase of 11.94 hairs per square centimeter, 7.36 hairs per square centimeter greater than placebo (P less than 0.05) [4, 5]. Target area hair width also improved significantly in the 1.0% BIW group versus placebo. No adverse sexual events were observed in any treatment group, distinguishing GT20029 from systemic 5-alpha-reductase inhibitors. The Phase II trial for acne vulgaris, conducted across 10 centers in China, also met its primary endpoint for total lesion count reduction (excluding nodules) at the 0.5% QD dose (P = 0.01 versus placebo), with both 0.5% and 1.0% QD groups achieving highly significant reductions in inflammatory lesion counts (P less than 0.01) [6].

On the basis of these results, Kintor has advanced GT20029 into Phase III clinical trials for male AGA in China and has initiated Phase II trials in the United States. The compound is not yet registered in any jurisdiction. The chemical structure of GT20029 has not been publicly disclosed; the molecular formula, molecular weight, and Chemical Abstracts Service registry number are not available in the public domain. This monograph reviews the available pharmacology, mechanism of action, preclinical and clinical evidence, pharmacokinetics, safety profile, handling considerations, and a comparative assessment of GT20029 against five alternative approaches to androgen-mediated dermatological conditions.